| 0.008 -0.009 (-52.38%) | 09-29 15:59 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0 | 1-year : | 0.01 |
| Resists | First : | 0 | Second : | 0.01 |
| Pivot price | 0 |
|||
| Supports | First : | 0 | Second : | 0 |
| MAs | MA(5) : | 0 | MA(20) : | 0 |
| MA(100) : | 0.06 |
MA(250) : | 0.23 |
|
| MACD | MACD : | -0.1  |
Signal : | -0.1 |
| %K %D | K(14,3) : | 18.1 |
D(3) : | 15.7 |
| RSI | RSI(14): 30.3 |
|||
| 52-week | High : | 0.76 | Low : | 0 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ INFI ] has closed above bottom band by 12.8%. Bollinger Bands are 98.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 37 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0 - 0 | 0 - 0 |
| Low: | 0 - 0 | 0 - 0 |
| Close: | 0 - 0 | 0 - 0 |
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Cambridge, Massachusetts.
Mon, 02 Oct 2023
Infinity comes to an end with Chapter 11 bankruptcy filing - Fierce Biotech
Sun, 17 Sep 2023
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Infinity - GlobeNewswire
Tue, 05 Sep 2023
Three execs leave Infinity Pharmaceuticals after failed merger, layoffs - The Business Journals
Mon, 24 Jul 2023
Rebuffed by MEI Pharma, Infinity scuttles merger and may face bankruptcy - Medical Marketing and Media
Mon, 24 Jul 2023
Infinity Pharmaceuticals Announces Termination of Merger Agreement with MEI Pharma - Business Wire
Fri, 16 Jun 2023
Why Clene Shares Are Trading Lower By 20%; Here Are 20 Stocks Moving Premarket - markets.businessinsider.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 91 (M) |
| Held by Insiders | 8.191e+007 (%) |
| Held by Institutions | 2.3 (%) |
| Shares Short | 919 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.992e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 570.4 % |
| Return on Equity (ttm) | -60.8 % |
| Qtrly Rev. Growth | 2.57e+006 % |
| Gross Profit (p.s.) | -10.87 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.27391e+007 |
| Qtrly Earnings Growth | -0.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -39 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.02 |
| Dividend | 0 |
| Forward Dividend | 2.21e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|